Aspirin, other antiplatelet agents, and anticoagulants

Clinical Trials in Heart Disease: A Companion to Braunwald's Heart Disease

Volumn , Issue , 2004, Pages 333-348

  Kurth, Tobias ^a   Buring, Julie E ^a   Ridker, Paul M ^a   Gaziano, J Michael ^b  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 77953426511     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7216-0408-4.50031-7     Document Type: Chapter

References (105)

1. Funk CD, Funk LB, Kennedy ME, et al. Human platelet/erythroleukemia cell prostaglandin G/H synthase: cDNA cloning, expression, and gene chromosomal assignment. FASEB J 1991, 5:2304-2312.
2. FitzGerald GA Mechanisms of platelet activation: Thromboxane A2 as an amplifying signal for other agonists. Am J Cardiol 1991, 68:11B-15B.
3. Vane JR Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nat N Biol 1971, 231:232-235.
4. Schafer AI Effects of nonsteroidal anti-inflammatory drugs on platelet function and systemic hemostasis. J Clin Pharmacol 1995, 35:209-219.
5. Pedersen AK, FitzGerald GA Cyclooxygenase inhibition, platelet function, and metabolite formation during chronic sulfinpyrazone dosing. Clin Pharmacol Ther 1985, 37:36-42.
6. Van Hecken A, Schwartz JI, Depre M, et al. Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen, and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 2000, 40:1109-1120.
7. Bombardier C, Laine L, Reicin A, et al. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis: VIGOR Study Group. N Engl J Med 2000, 343:1258-1520.
8. Solomon DH, Glynn RJ, Levin R, et al. Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 2002, 162:1099-1104.
9. Rahme E, Pilote L, LeLorier J Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 2002, 162:1111-1115.
10. Watson DJ, Rhodes T, Cai B, et al. Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 2002, 162:1105-1110.
11. Ray WA, Stein CM, Hall K, et al. Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: An observational cohort study. Lancet 2002, 359:118-123.
12. Garcia Rodriguez LA, Varas C, Patrono C Differential effects of aspirin and non-aspirin nonsteroidal antiinflammatory drugs in the primary prevention of myocardial infarction in postmenopausal women. Epidemiology 2000, 11:382-387.
13. Whitlon DS, Sadowski JA, Suttie JW Mechanism of coumarin action: Significance of vitamin K epoxide reductase inhibition. Biochemistry 1978, 17:1371-1377.
14. Hirsh J, Fuster V, Ansell J, et al. American Heart Association/American College of Cardiology Foundation guide to warfarin therapy. J Am Coll Cardiol 2003, 41:1633-1652.
15. Elwood PC, Cochrane AL, Burr ML, et al. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. BMJ 1974, 1:436-440.
16. Elwood PC, Sweetnam PM Aspirin and secondary mortality after myocardial infarction. Lancet 1979, 2:1313-1315.
17. Elwood PC, Sweetnam PM Aspirin and secondary mortality after myocardial infarction. Circulation 1980, 62:V53-V58.
18. Coronary Drug Project Research Group Aspirin in coronary heart disease. J Chronic Dis 1976, 29:625-642.
19. Aspirin Myocardial Infarction Study Research Group A randomized, controlled trial of aspirin in persons recovered from myocardial infarction. JAMA 1980, 243:661-669.
20. Persantine-Aspirin Reinfarction Study Research Group Persantine and aspirin in coronary heart disease. Circulation 1980, 62:449-461.
21. Klimt CR, Knatterud GL, Stamler J, et al. Persantine-Aspirin Reinfarction Study. Part II. Secondary coronary prevention with persantine and aspirin. J Am Coll Cardiol 1986, 7:251-269.
22. Breddin K, Loew D, Lechner K, et al. Secondary prevention of myocardial infarction: A comparison of acetylsalicylic acid, placebo and phenprocoumon. Haemostasis 1980, 9:325-344.
23. Anturane Reinfarction Trial Group Sulfinpyrazone in the prevention of cardiac death after myocardial infarction. N Engl J Med 1978, 298:289-295.
24. Anturane Reinfarction Trial Research Group Sulfinpyrazone in the prevention of sudden death after myocardial infarction. N Engl J Med 1980, 302:250-256.
25. Anturane Reinfarction Italian Study Group Sulfinpyrazone in post-myocardial infarction. Report from the Anturane Reinfarction Italian Study. Lancet 1982, 1:237-242.
26. Antiplatelet Trialists' Collaboration Secondary prevention of vascular disease by prolonged antiplatelet therapy. BMJ 1988, 296:320-332.
27. Antiplatelet Trialists' Collaboration Collaborative overview of randomised trials of antiplatelet treatment: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994, 308:81-106.
28. Antithrombotic Trialists' Collaboration Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86.
29. International Stroke Trial Collaborative Group The International Stroke Trial (IST): A randomised trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischaemic stroke. Lancet 1997, 349:1569-1581.
30. CAST (Chinese Acute Stroke Trial) Collaborative Group.CA.S.T Randomised placebo-controlled trial of early aspirin use in 20,000 patients with acute ischaemic stroke. Lancet 1997, 349:1641-1649.
31. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996, 143:1-13.
32. De Schryver EL Design of ESPRIT: An international randomized trial for secondary prevention after non-disabling cerebral ischaemia of arterial origin. European/Australian Stroke Prevention in Reversible Ischaemia Trial (ESPRIT) group. Cerebrovasc Dis 2000, 10:147-150.
33. CAPRIE Steering Committee A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996, 348:1329-1339.
34. CURE I. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
35. Hacke W From CURE to MATCH: ADP receptor antagonists as the treatment of choice for high-risk atherothrombotic patients. Cerebrovasc Dis 2002, 13(1):22-26.
36. Gaspoz JM, Coxson PG, Goldman PA, et al. Cost effectiveness of aspirin, clopidogrel, or both for secondary prevention of coronary heart disease. N Engl J Med 2002, 346:1800-1806.
37. Schomig A, Neumann FJ, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996, 334:1084-1089.
38. UK-TIA Study Group United Kingdom Transient Ischemic Attack (UK-TIA) aspirin trial: Final results. J Neurol Neurosurg Psychiatry 1991, 54:1044-1054.
39. Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ Association between aspirin and upper gastrointestinal complications: Systematic review of epidemiologic studies. Br J Clin Pharmacol 2001, 52:563-571.
40. Loll PJ, Picot D, Ekabo O, et al. Synthesis and use of iodinated nonsteroidal antiinflammatory drug analogs as crystallographic probes of the prostaglandin H2 synthase cyclooxygenase active site. Biochemistry 1996, 35:7330-7340.
41. Loll PJ, Picot D, Garavito RM The structural basis of aspirin activity inferred from the crystal structure of inactivated prostaglandin H2 synthase. Nat Struct Biol 1995, 2:637-643.
42. Livio M, Del Maschio A, Cerletti C, et al. Indomethacin prevents the long-lasting inhibitory effect of aspirin on human platelet cyclo-oxygenase activity. Prostaglandins 1982, 23:787-796.
43. Rao GH, Johnson GG, Reddy KR, et al. Ibuprofen protects platelet cyclooxygenase from irreversible inhibition by aspirin. Arteriosclerosis 1983, 3:383-388.
44. Catella-Lawson F, Reilly MP, Kapoor SC, et al. Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 2001, 345:1809-1817.
45. MacDonald TM, Wei L Effect of ibuprofen on cardioprotective effect of aspirin. Lancet 2003, 361:573-574.
46. Steering Committee of the Physicians' Health Study Research Group Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989, 321:129-135.
47. Kurth T, Glynn RG, Walker AM, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. Circulation 2003, 108:1191-1195.
48. Murata T, Ushikubi F, Matsuoka T, et al. Altered pain perception and inflammatory response in mice lacking prostacyclin receptor. Nature. 1997, 388:678-682.
49. FitzGerald GA, Patrono C The coxibs, selective inhibitors of cyclooxygenase-2. N Engl J Med. 2001, 345:433-442.
50. Silverstein FE, Faich G, Goldstein JL, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: A randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA. 2000, 284:1247-1255.
51. Wright IS, Marple CD, Beck DF Report of the Committee for the Evaluation of Anticoagulants in the Treatment of Coronary Thrombosis with Myocardial Infarction. Am Heart J 1948, 36:801-815.
52. Tulloch JA, Gilchrist AR Anticoagulants in treatment of coronary thrombosis. BMJ 1950, 2:965-971.
53. Wright IS The use of anticoagulants in coronary heart disease: Progress and problems-1960. Circulation 1960, 22:608-618.
54. Wasserman AJ, Gutterman LA, Yoe KB, et al. Anticoagulants in acute myocardial infarction. The failure of anticoagulants to alter mortality in a randomized series. Am Heart J 1966, 71:43-49.
55. Loeliger EA, Hensen A, Kroes F, et al. A double-blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1967, 182:549-566.
56. Borchgrevink CF, Bjerkelund C, Abrahamsen AM, et al. Long-term anticoagulant therapy after myocardial infarction in women. BMJ 1968, 3:571-574.
57. Drapkin A, Merskey C Anticoagulant therapy after acute myocardial infarction: Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972, 222:541-548.
58. Ritland S, Lygren T Comparison of efficacy of 3 and 12 months' anticoagulant therapy after myocardial infarction: A controlled clinical trial. Lancet 1969, 1:122-124.
59. Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council Assessment of short-anticoagulant administration after cardiac infarction. Report of the Working Party on Anticoagulant Therapy in Coronary Thrombosis to the Medical Research Council. BMJ 1969, 1:335-342.
60. Ebert RV Long-term anticoagulant therapy after myocardial infarction: Final report of the Veterans Administration cooperative study. JAMA 1969, 207:2263-2267.
61. Seaman AJ, Griswold HE, Reaume RB, et al. Long-term anticoagulant prophylaxis after myocardial infarction. N Engl J Med 1969, 281:115-119.
62. Meuwissen OJ, Vervoorn AC, Cohen O, et al. Double blind trial of long-term anticoagulant treatment after myocardial infarction. Acta Med Scand 1969, 186:361-368.
63. Mitchell JR Anticoagulants in coronary heart disease: Retrospect and prospect. Lancet 1981, 1:257-262.
64. Sixty Plus Reinfarction Study Research Group A double-blind trial to assess long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Lancet 1980, 2:989-994.
65. Sixty Plus Reinfarction Study Research Group Risks of long-term oral anticoagulant therapy in elderly patients after myocardial infarction. Second report of the Sixty Plus Reinfarction Study Research Group. Lancet 1982, 1:64-68.
66. Smith P, Arnesen H, Holme I The effect of warfarin on mortality and reinfarction after myocardial infarction. N Engl J Med 1990, 323:147-152.
67. Anticoagulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECT) Research Group Effect of long-term oral anticoagulant treatment on mortality and cardiovascular morbidity after myocardial infarction. Lancet 1994, 343:499-503.
68. Anand SS, Yusuf S Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis. JAMA 1999, 282:2058-2067.
69. EPSIM Research Group A controlled comparison of aspirin and oral anticoagulants in prevention of death after myocardial infarction. N Engl J Med 1982, 307:701-708.
70. Julian DG, Chamberlain DA, Pocock SJ A comparison of aspirin and anticoagulation following thrombolysis for myocardial infarction (the AFTER study): A multicentre unblinded randomised clinical trial. BMJ 1996, 313:1429-1431.
71. Meijer A, Verheugt FW, Werter CJ, et al. Aspirin versus Coumadin in the prevention of reocclusion and recurrent ischemia after successful thrombolysis: A prospective placebo-controlled angiographic study: Results of the APRICOT Study. Circulation 1993, 87:1524-1530.
72. Cohen M, Adams PC, Parry G, et al. Combination antithrombotic therapy in unstable rest angina and non-Q-wave infarction in non-prior aspirin users: Primary end points analysis from the ATACS trial. Antithrombotic Therapy in Acute Coronary Syndromes Research Group. Circulation 1994, 89:81-88.
73. Altman R, Boullon F, Rouvier J, et al. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. J Thorac Cardiovasc Surg 1976, 72:127-129.
74. Coumadin Aspirin Reinfarction Study (CARS) Investigators Randomised double-blind trial of fixed low-dose warfarin with aspirin after myocardial infarction. Lancet 1997, 350:389-396.
75. Altman R, Rouvier J, Gurfinkel E, et al. Comparison of two levels of anticoagulant therapy in patients with substitute heart valves. J Thorac Cardiovasc Surg 1991, 101:427-431.
76. Fiore LD, Ezekowitz MD, Brophy MT, et al. Department of Veterans Affairs Cooperative Studies Program clinical trial comparing combined warfarin and aspirin with aspirin alone in survivors of acute myocardial infarction: Primary results of the CHAMP Study. Circulation 2002, 105:557-563.
77. The Organization to Assess Strategies for Ischemic Syndromes (OASIS) Investigators Effects of long-term, moderate-intensity oral anticoagulation in addition to aspirin in unstable angina. J Am Coll Cardiol. 2001, 37:475-484.
78. van Es RF, Jonker JJ, Verheugt FW, et al. Aspirin and Coumadin after acute coronary syndromes (the ASPECT-2 study): A randomised controlled trial. Lancet 2002, 360:109-113.
79. Hurlen M, Abdelnoor M, Smith P, et al. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002, 347:969-974.
80. Brouwer MA, van den Bergh PJPC, Aengevaeren WRM, et al. Aspirin plus coumarin versus aspirin alone in the prevention of reocclusion after fibrinolysis for acute myocardial infarction: Results of the Antithrombotics in the Prevention of Reocclusion in Coronary Thrombosis (APRICOT)-2 trial. Circulation 2002, 106:659-665.
81. Medical Research Council's General Practice Research Framework.Thrombosis Prevention Trial Randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998, 351:233-241.
82. Wallentin L, Wilcox RG, Weaver WD, et al. Oral ximelagatran for secondary prophylaxis after myocardial infarction: The ESTEEM randomised controlled trial. Lancet. 2003, 362:789-797.
83. Smith SCJ, Blair SN, Bonow O, et al. AHA/ACC Guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 2001, 104:1577-1579.
84. Peto R, Gray R, Collins R, et al. A randomised trial of the effects of prophylactic daily aspirin among male British doctors. BMJ 1988, 296:313-316.
85. Ridker PM, Manson JE, Buring JE, et al. The effect of chronic platelet inhibition with low-dose aspirin on atherosclerotic progression and acute thrombosis: Clinical evidence from the Physicians' Health Study. Am Heart J 1991, 122:1588-1592.
86. Manson JE, Grobbee DE, Stampfer MJ, et al. Aspirin in the primary prevention of angina pectoris in a randomized trial of US physicians. Am J Med 1990, 89:772-776.
87. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the Hypertension Optimal Treatment (HOT) randomized trial. Lancet. 1998, 351:1755-1762.
88. deGaetano G, for the Collaborative Group of the Primary Prevention Project (PPP) Low-dose aspirin and vitamin E in people at cardiovascular risk: A randomised trial in general practice. Lancet 2001, 357:89-95.
89. Hayden M, Pignone M, Phillips C, et al. Aspirin for the primary prevention of cardiovascular events: A summary of the evidence for the US Preventive Services Task Force. Ann Intern Med 2002, 136:161-172.
90. Hart RG, Halperin JL, McBride R, et al. Aspirin for the primary prevention of stroke and other major vascular events: Meta-analysis and hypotheses. Arch Neurol 2000, 57:326-332.
91. Sudlow C Antithrombotic treatment. American College of Physicians-American Society of Internal Medicine, ed. Clinical Evidence 2001, BMJ Publishing Group, London.
92. Eidelman RS, Hebert PR, Weisman SM, et al. An update on aspirin in the primary prevention of cardiovascular disease. Arch Intern Med. 2003, 163:2006-2010.
93. Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: The HOT Study. J Hypertens 2000, 18:629-642.
94. Rexrode KM, Lee IM, Cook NR, et al. Baseline characteristics of participants in the Women's Health Study. J Women's Health Gender-Based Med 2000, 9:19-27.
95. Hamsten A, de Faire U, Walldius G, et al. Plasminogen activator inhibitor in plasma: Risk factor for recurrent myocardial infarction. Lancet 1987, 2:3-9.
96. Ridker PM, Vaughan DE, Stampfer MJ, et al. Endogenous tissue-type plasminogen activator and risk of myocardial infarction. Lancet 1993, 341:1165-1168.
97. Thompson SG, Kienast J, Pyke SD, et al. Hemostatic factors and the risk of myocardial infarction or sudden death in patients with angina pectoris: European Concerted Action on Thrombosis and Disabilities Angina Pectoris Study Group. N Engl J Med 1995, 332:635-641.
98. Ridker PM, Hennekens CH, Cerskus A, et al. Plasma concentration of cross-linked fibrin degradation product (D-dimer) and the risk of future myocardial infarction among apparently healthy men. Circulation 1994, 90:2236-2240.
99. Ridker PM, Cushman M, Stampfer MJ, et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997, 336:973-979.
100. Ridker PM, Cushman M, Stampfer MJ, et al. Plasma concentration of C-reactive protein and risk of developing peripheral vascular disease. Circulation 1998, 97:425-428.
101. Ridker PM, Rifai N, Rose L, et al. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002, 347:1557-1565.
102. Kennon S, Price CP, Mills PG, et al. The effect of aspirin on C-reactive protein as a marker of risk in unstable angina. J Am Coll Cardiol. 2001, 37:1266-1270.
103. US Preventive Services Task Force Aspirin for the primary prevention of cardiovascular events: Recommendation and rationale. Ann Intern Med 2002, 136:157-160.
104. Wilson PW, D'Agostino RB, Levy D, et al. Prediction of coronary heart disease using risk factor categories. Circulation 1998, 97:1837-1847.
105. Pearson TA, Blair SN, Daniels SR, et al. AHA guidelines for primary prevention of cardiovascular disease and stroke: 2002 update. Circulation 2002, 106:388-391.